Gene therapy could have worldwide market of ~$21.6 trln - Guggenheim

Sio Gene Therapies

04/09/2019 12:47

** Ongoing pre-clinical and clinical gene therapy programs
have an addressable market size of about 2.4 bln patients across
the world, Guggenheim says
    ** Gene therapy is a technique that uses genes as opposed to
drugs or surgery, to treat or prevent diseases 
    ** Brokerage says gene therapies currently in development
for rare diseases have the potential to treat 12.8 mln patients
worldwide; says about 94% of the 126 ongoing trials are in rare
disorders
    ** Assuming a mean cost of $1.5 mln/patient for a therapy,
gene therapies for rare diseases make up a total addressable
market of $19.2 trillion, brokerage says
    ** Says larger conditions such as chronic lung disease,
glaucoma, hearing loss and Parkinson's disease, total 2.5 bln
addressable patients representing an additional sales
opportunity of $2.4 trillion assuming $10,000/patient for a gene
therapy 
    ** There are >229 gene therapy clinical trials currently for
over 100 conditions, brokerage says
    ** Novartis AG  NOVN.S , AstraZeneca Plc  AZN.L , Regenxbio
Inc  RGNX.O  among the companies developing gene therapies for
larger indications

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))